STOCK TITAN

Sanofi - $SNY STOCK NEWS

Welcome to our dedicated page for Sanofi news (Ticker: $SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi stock.

Sanofi American Depositary Shares (symbol: SNY) represent a large global healthcare company headquartered in Paris, France, established in 1973. Sanofi specializes in the development and marketing of pharmaceuticals, specifically focusing on oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments, and vaccines. One of its most significant achievements includes the successful launch of Dupixent, a drug that accounts for over 20% of the company's total sales, although profits are shared with Regeneron.

Sanofi's Global Presence
Approximately 40% of Sanofi's revenue comes from the United States, 25% from Europe, and the remaining largely from emerging markets. This diversified revenue stream underscores Sanofi's global reach and adaptability in various healthcare markets.

Recent Developments
Sanofi has been active in strategic mergers and acquisitions to enhance its product portfolio. For instance, in January 2024, Sanofi announced the acquisition of Inhibrx's assets related to INBRX-101, a therapy for alpha-1 antitrypsin deficiency. This acquisition is valued at approximately $2.2 billion and aims to expand Sanofi's capabilities in rare diseases.

Partnerships and Innovations
Sanofi has also entered into a co-exclusive licensing agreement with Novavax to co-commercialize Novavax's adjuvanted COVID-19 vaccine globally, excluding certain regions where Novavax already has agreements. This partnership is expected to enhance Novavax's COVID-19 vaccine reach and combine it with Sanofi's flu vaccines for a more comprehensive approach to respiratory diseases.

Sustainability and Social Responsibility
Sanofi is committed to sustainability and social responsibility, aiming to improve healthcare access and outcomes worldwide. The company emphasizes eco-friendly practices and actively pursues projects that align with these values.

Financial Outlook
Sanofi continues to invest in research and development to drive future growth and innovation. The company's robust financial health allows it to navigate market challenges and capitalize on new opportunities in the pharmaceutical sector.

Rhea-AI Summary

I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
management
-
Rhea-AI Summary

Novavax reported its financial results and operational highlights for Q1 2024, including a co-exclusive licensing agreement with Sanofi for COVID-19 vaccines, a Phase 3 trial for a combination flu-COVID-19 vaccine, and a standalone influenza vaccine. The agreement holds potential multi-billion dollar revenue opportunities for Novavax, including upfront payments, equity investments, milestones, and royalties. Novavax also reduced liabilities by $831 million and achieved $94 million in revenue for Q1 2024. The company's financial position improved, with reduced losses and cash reserves of $496 million as of March 31, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.66%
Tags
-
Rhea-AI Summary

Novavax and Sanofi have entered into a co-exclusive licensing agreement to co-commercialize a protein-based COVID-19 vaccine and develop novel COVID-19-Influenza combination vaccines. The agreement provides broader access to the vaccine from 2025 onwards and includes a cash and equity investment of approximately $1.2 billion for Novavax. This collaboration aims to accelerate the development of a combination product based on authorized vaccines for enhanced convenience and protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.66%
Tags
covid-19
Rhea-AI Summary
Sobi® received a positive CHMP opinion recommending approval of efanesoctocog alfa for the treatment of haemophilia A. The therapy offers once-weekly dosing, providing patients with sustained factor VIII activity levels, significantly improving protection from bleeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary
Sanofi launches Verorab® in the UK, an inactivated rabies vaccine for pre-exposure and post-exposure prophylaxis. Clinical trials show high immune response and long-term protection. Rabies is fatal but preventable, with millions vaccinated worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary
Synthekine Inc. announced a collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. Synthekine will receive a $40 million upfront payment and is eligible for additional milestones and royalties on net sales. The collaboration aims to develop selective agonists that expand therapeutic index, focusing on advancing Synthekine’s multiple approaches to optimizing IL-10. Sanofi will assume sole responsibility for subsequent preclinical, clinical, and commercial activities for the IL-10 therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) have entered into a definitive agreement under which Sanofi will acquire all assets and liabilities associated with INBRX-101. Inhibrx shareholders will receive $30 per share in cash, a CVR of $5, and 0.25 shares in New Inhibrx. Sanofi will pay off Inhibrx's outstanding debt and capitalize New Inhibrx with $200 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
none
-
Rhea-AI Summary
Scribe Therapeutics Inc. (SNY) announces that Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics. The ongoing collaboration aims to advance in vivo genetic medicines using Scribe’s CRISPR by Design™ approach. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none

FAQ

What does Sanofi specialize in?

Sanofi specializes in pharmaceuticals, focusing on oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments, and vaccines.

Where is Sanofi headquartered?

Sanofi is headquartered in Paris, France.

What is Dupixent?

Dupixent is a drug developed by Sanofi that accounts for over 20% of the company's sales, focusing on treating multiple conditions including asthma and dermatitis.

What recent acquisitions has Sanofi made?

Sanofi recently acquired Inhibrx's assets related to INBRX-101, a therapy for alpha-1 antitrypsin deficiency, valued at approximately $2.2 billion.

Who are Sanofi's primary markets?

Sanofi's primary markets include the United States (40% of revenue), Europe (25% of revenue), and various emerging markets.

What is the recent partnership between Sanofi and Novavax about?

Sanofi has partnered with Novavax to co-commercialize Novavax's adjuvanted COVID-19 vaccine globally, excluding some regions, and combine it with Sanofi's flu vaccines.

How does Sanofi approach sustainability?

Sanofi places a strong emphasis on sustainability and social responsibility, aiming to adopt eco-friendly practices and improve healthcare outcomes globally.

What percentage of Sanofi's revenue comes from the United States?

Approximately 40% of Sanofi's revenue comes from the United States.

What is the financial health of Sanofi?

Sanofi has a robust financial health, enabling it to invest in research and development and capitalize on new market opportunities.

What are Sanofi's future growth plans?

Sanofi plans to continue investing in research and development to drive innovation and future growth in the pharmaceutical sector.

Sanofi

Nasdaq:SNY

SNY Rankings

SNY Stock Data

115.72B
1.10B
0%
9.94%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Paris